What is Binimetinib Patent WO2003077914A1?
Patent WO2003077914A1 relates to binimetinib, a MEK inhibitor. It claims compounds, including binimetinib, for treating conditions like cancer [1]. The patent was filed by Array BioPharma, Inc. [1].
When does Binimetinib's Patent Protection Expire?
The patent WO2003077914A1 is associated with binimetinib, which has a patent expiry date linked to its regulatory approvals and exclusivities. For specific and up-to-date patent expiry information for binimetinib, including any granted exclusivities, DrugPatentWatch.com can provide detailed insights [2].
What are MEK Inhibitors Like Binimetinib Used For?
Binimetinib is used in combination with encorafenib to treat patients with unresectable or metastatic melanoma with specific BRAF mutations [3]. MEK inhibitors target the MEK pathway, which is often overactive in certain cancers and contributes to cell growth and survival [4].
How is Binimetinib Approved and Regulated?
Binimetinib, marketed as Mektovi, received approval from the U.S. Food and Drug Administration (FDA) in 2018 as a combination therapy for melanoma [3]. Regulatory approval involves extensive clinical trials to demonstrate safety and efficacy.
What are the Risks and Side Effects of Binimetinib?
Common side effects associated with binimetinib, particularly in combination therapy, can include fatigue, nausea, diarrhea, vomiting, abdominal pain, and rash [3]. More serious risks can involve heart problems, vision issues, and skin reactions [3].
Who are the Competitors to Binimetinib?
The competitive landscape for melanoma treatments includes other targeted therapies and immunotherapies. Specifically, other MEK inhibitors and BRAF inhibitors are direct competitors. Drugs like cobimetinib and trametinib, also MEK inhibitors, are used in similar indications [5].
What is the Mechanism of Action for Binimetinib?
Binimetinib works by inhibiting MEK1 and MEK2 proteins. These proteins are part of the RAS/RAF/MEK/ERK signaling pathway, which plays a critical role in cell proliferation and survival. By blocking MEK, binimetinib can slow or stop the growth of cancer cells that rely on this pathway for growth [4].
Can Biosimilars Be Developed for Binimetinib?
The development of biosimilars for biologic drugs is a complex process. For small molecule drugs like binimetinib, the concept of "generics" is more applicable than biosimilars. Generic versions can be developed and approved after patent and exclusivity protections expire, demonstrating bioequivalence to the reference product [6].
What are the Patents Surrounding Binimetinib Beyond WO2003077914A1?
Array BioPharma, now part of Pfizer, holds multiple patents related to binimetinib and its use [1]. Additional patents may cover manufacturing processes, formulations, and new indications. Exploring patent databases like DrugPatentWatch.com can reveal a comprehensive list of related patents and their timelines [2].
How Does Binimetinib Differ from Other Targeted Cancer Therapies?
Binimetinib is a targeted therapy that specifically inhibits the MEK enzyme. Unlike traditional chemotherapy, which affects all rapidly dividing cells, targeted therapies like binimetinib are designed to attack specific molecules or pathways that are essential for cancer cell growth, often with fewer side effects on healthy cells [4]. Its combination with encorafenib addresses specific genetic mutations (BRAF V600E/K) found in melanoma [3].
What are the Clinical Trial Results for Binimetinib?
Clinical trials for binimetinib, often in combination with encorafenib, have demonstrated significant improvements in progression-free survival and overall survival for patients with BRAF-mutated melanoma compared to chemotherapy [3]. These results formed the basis for its regulatory approvals.
What is the Patient Perspective on Binimetinib Treatment?
Patients receiving binimetinib as part of combination therapy typically seek to improve their prognosis and quality of life. While effective, patients are often concerned about managing side effects and adhering to treatment regimens [3]. Access to information about the drug's efficacy, side effects, and cost is crucial for informed decision-making.
Sources
1. WO2003077914A1 - https://patents.google.com/patent/WO2003077914A1/
2. DrugPatentWatch.com - https://drugpatentwatch.com/
3. U.S. Food and Drug Administration (FDA). (2018). FDA approves combination of encorafenib and binimetinib for BRAF V600E or V600K mutant unresectable or metastatic melanoma. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-combination-encorafenib-and-binimetinib-braf-v600e-or-v600k-mutant-unresectable-or
4. Arrone, M., Garofalo, A., & Chiari, R. (2016). Binimetinib (MEK162): a selective MEK inhibitor for the treatment of cancer. Future Oncology, 12(22), 2557-2571. https://www.futuremedicine.com/doi/10.2217/fon-2016-0223
5. Hsu, J., & Puzanov, I. (2017). MEK inhibitors in melanoma. Seminars in Oncology, 44(4), 259-267. https://www.sciencedirect.com/science/article/abs/pii/S009377501730146X
6. U.S. Food and Drug Administration (FDA). (2020). Generics: An Introduction. https://www.fda.gov/drugs/generic-drugs/generics-introduction